Table 1 Demographic and disease characteristics at baseline

From: Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia

  Patients with newly diagnosed AML N = 39
Age (years), median (range) 77 (58–87)
  Age ≥75 years, n(%) 24 (62)
Sex, n(%)
Male 28 (72)
 Female 11 (28)
AML classification,* n(%)
 Myelodysplasia-related changes 14 (36)
 Recurrent genetic abnormalities 2 (5)
Therapy-related myeloid neoplasms 2 (5)
 Not otherwise specified 20 (51)
 Missing 1 (3)
Months since initial diagnosis, median (range) 1.0 (0.1–4.7)
Antecedent hematologic disorder,a n(%) 23 (59)
Cytogenetic risk status, n(%)
 Intermediate-risk 19 (49)
 Poor-risk 10 (26)
 Missing 9 (23)
ECOG performance status score, n(%)
 0 12 (31)
 1 18 (46)
 2 9 (23)
IDH2 mutant allele, n(%)
 R140 26 (67)
 R172 12 (31)
 Other/Missing 1 (3)
ELN risk classification, n(%)
 Favorable 1 (3)
 Intermediate 9 (23)
 Adverse 25 (64)
 Not assessable 4 (10
Bone marrow blasts (%),b median (range) 39 (14–92)
Hematology, mean (SD)
 WBC (109/L) 5.8 (7.0)
 Hemoglobin (g/dL) 9.1 (10.4)
 Platelet (109/L) 89 (92)
Transfusion dependent, n(%)
 RBC 30 (77)
 Platelets 19 (49)